Investor's Business Daily on MSN

Sarepta Loses A Third Of Its Value On Failed Tests, Gene Therapy Outlook

Sarepta stock crashed Tuesday after the biotech company said two of its muscular dystrophy drugs failed confirmatory tests.

Sarepta Says Older Muscle Disease Drugs Failed Confirmatory Trial

Sarepta Therapeutics Inc. shares plunged after a trial designed to confirm the benefits of two of its older drugs failed to show clear patient improvement, raising questions about their future.The ...